Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Most Active List

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Aug 04, 2021 11:53am

231 Views

Post# 33648403

RE:Most Active List

Without hearing / reading the results from Antibe's follow on deep dives this question cannot be answered as there are many variables that could influence next steps. I'd start by looking at the past studies esp PH2 and looking at the safety profiles in their corp slide deck and form some intial thoughts / opinions beforehand

https://secureservercdn.net/72.167.241.46/ln9.cea.myftpupload.com/wp-content/uploads/2021/07/Antibe-Corporate-Presentation-July-2021.pdf

"The Company will continue to collect and analyze additional data over the next several weeks to understand the cause and implications of these events and to determine the optimal plan for the continued development of otenaproxesul.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1